MYC and diffuse large B-cell lymphoma: Of note, constitutive DDR activation correlates with MYC levels predicting poor prognosis [29], and therapeutic approaches targeting DDR through inhibition of the Ataxia teleangiectasia and Rad3 related (ATR)-checkpoint kinase 1/2 (CHK1/2) axis showed efficacy in preclinical models of MYC-positive DLBCL, including those with TP53 mutations/deletions and CDKN2A loss which are mechanistically linked to anthracycline resistance [30–33].